JCAR 014

Drug Profile

JCAR 014

Alternative Names: 4-1BB-modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19-4-1BB-zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/4-1BB/zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; JCAR014

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Juno Therapeutics
  • Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics; MedImmune; National Cancer Institute (USA)
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse events data from a phase I/II trial in Chronic lymphocytic leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 07 Sep 2016 Updated safety and efficacy data from a phase I/II trial in Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma released by Juno Therapeutics
  • 04 Jun 2016 Updated safety and efficacy results from a phase I/II trial in Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma released by Juno Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top